ASSURE S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.
作者信息
Porta Camillo, Chiellino Silvia
机构信息
Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy; ; Italian Group of Onco-Nephrology (Gruppo Italiano di Oncologia Nefrologica/GION), Pavia, Italy.
Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
出版信息
Ann Transl Med. 2016 Oct;4(Suppl 1):S14. doi: 10.21037/atm.2016.10.45.
Abstract
摘要
相似文献
1
ASSURE S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics.ASSURE S-TRAC：靶向药物和基因组学时代肾癌辅助治疗的矛盾结果。
Ann Transl Med. 2016 Oct;4(Suppl 1):S14. doi: 10.21037/atm.2016.10.45.
2
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.高危局限性肾癌的辅助治疗：新证据与未来临床试验
J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4.
3
Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.辅助治疗在非转移性肾细胞癌中的应用：文献综述。
Clin Genitourin Cancer. 2018 Jun;16(3):176-183. doi: 10.1016/j.clgc.2018.01.003. Epub 2018 Feb 2.
4
Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database.我们是否需要针对接受手术治疗的肾癌患者制定新的高风险标准，以改善未来辅助治疗临床试验的结果？基于多中心CORONA数据库的综合分析结果。
Eur J Surg Oncol. 2016 May;42(5):744-50. doi: 10.1016/j.ejso.2016.01.009. Epub 2016 Jan 22.
5
Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.评估当代辅助临床试验中的病理纳入标准，以预测肾细胞癌肾切除术后疾病进展。
Cancer. 2012 Sep 15;118(18):4412-20. doi: 10.1002/cncr.26695. Epub 2012 Jan 3.
6
Adjuvant therapy in renal cell carcinoma: the perspective of urologists.肾细胞癌的辅助治疗：泌尿科医生的观点。
Int J Clin Oncol. 2019 Jun;24(6):694-697. doi: 10.1007/s10147-019-01398-x. Epub 2019 Feb 13.
7
Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.辅助性舒尼替尼用于高危切除性肾细胞癌：ASSURE和S-TRAC试验的荟萃分析
Ann Oncol. 2017 Apr 1;28(4):898-899. doi: 10.1093/annonc/mdw667.
8
Adjuvant therapy after nephrectomy for renal cell carcinoma.肾细胞癌肾切除术后的辅助治疗。
Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:33-36. doi: 10.1111/ajco.13056.
9
Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.肾切除术后高危肾细胞癌的辅助治疗：有多少试验结果呈阳性？是只有一项还是不止一项？
Asia Pac J Clin Oncol. 2020 Sep;16 Suppl 3:12-17. doi: 10.1111/ajco.13314.
10
A new approach to kidney wait-list management in the kidney allocation system era: Pilot implementation and evaluation.肾脏分配系统时代的新肾脏候补者名单管理方法：试点实施与评估。
Clin Transplant. 2018 Nov;32(11):e13406. doi: 10.1111/ctr.13406. Epub 2018 Oct 15.
引用本文的文献
1
Endoplasmic Reticulum Stress in Renal Cell Carcinoma.内质网应激与肾细胞癌。
Int J Mol Sci. 2023 Mar 3;24(5):4914. doi: 10.3390/ijms24054914.
2
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology.辅助治疗中实体瘤的免疫检查点抑制剂：当前进展、未来方向及在移植肿瘤学中的作用
Cancers (Basel). 2023 Feb 23;15(5):1433. doi: 10.3390/cancers15051433.
3
Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.“复发高危”肾癌术后辅助治疗是否有作用？当前概念的更新
Curr Oncol. 2018 Oct;25(5):e444-e453. doi: 10.3747/co.25.3865. Epub 2018 Oct 31.
4
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.舒尼替尼治疗肾细胞癌：近期证据更新
Ther Adv Urol. 2017 Jun 29;9(8):195-207. doi: 10.1177/1756287217713902. eCollection 2017 Aug.
5
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.高危非转移性肾细胞癌的腹膜后淋巴结清扫术：ASSURE（ECOG-ACRIN 2805）辅助试验分析
J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.
本文引用的文献
1
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.辅助舒尼替尼治疗肾切除术后高危肾细胞癌。
N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.
2
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.舒尼替尼或索拉非尼辅助治疗高危、非转移性肾细胞癌（ECOG-ACRIN E2805）：一项双盲、安慰剂对照、随机3期试验。
Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9.
3
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.一种用于预测局限性肾细胞癌手术后复发的 16 基因检测：开发和验证研究。
Lancet Oncol. 2015 Jun;16(6):676-85. doi: 10.1016/S1470-2045(15)70167-1. Epub 2015 May 12.
4
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.宿主免疫状态对接受靶向治疗的晚期复发性肾细胞癌患者的预后意义。
Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6.
5
Adjuvant therapy for renal cell carcinoma: past, present, and future.肾细胞癌的辅助治疗：过去、现在与未来。
Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26.
6
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.国际泌尿病理学会（ISUP）肾细胞癌分级系统及其他预后参数。
Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb.
7
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.辅助治疗肾细胞癌切除术：所有策略的效果都一样差吗？靶向药物临床试验设计的潜在影响。
Clin Genitourin Cancer. 2013 Dec;11(4):471-6. doi: 10.1016/j.clgc.2013.04.018. Epub 2013 Jun 28.
8
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.散发性透明细胞肾细胞癌中 BAP1 和 PBRM1 突变对生存的影响：一项回顾性分析及独立验证
Lancet Oncol. 2013 Feb;14(2):159-167. doi: 10.1016/S1470-2045(12)70584-3. Epub 2013 Jan 16.
9
The VHL/HIF axis in clear cell renal carcinoma.VHL/HIF 轴在肾透明细胞癌中的作用。
Semin Cancer Biol. 2013 Feb;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001. Epub 2012 Jun 13.
10
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.VEGF抑制作用逆转后肿瘤内血管的快速再生。
J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612.
Zotero 插件